Using antibodies to target cancer therapeutics

Expert Opinion on Biological Therapy

Volumn 12, Issue 9, 2012, Pages 1173-1190

  Goldenberg, David M ^a   Sharkey, Robert M ^a  

^a CENTER FOR MOLECULAR MEDICINE AND IMMUNOLOGY   (United States)

Author keywords

Antibody therapy; Antibody drug conjugates; Immunocytokines; Immunotoxins; Radioimmunoconjugates

Indexed keywords

AGS 22M6E; ANTI CD70 AURISTATIN F; ANTI CHOLINE TRANSPORTER LIKE PROTEIN 4 AURISTATIN E; ANTI MESOTHELIN MAYTANSINOID DM4; ANTI NECTIN 4 AURISTATIN E; ANTIBODY CONJUGATE; ASG 5ME; BRENTUXIMAB VEDOTIN; CD19 ANTIGEN; CLIVATUZUMAB TETRAXETAN Y 90; DENILEUKIN DIFTITOX; EPRATUZUMAB TETRAXETAN YTTRIUM Y 90; FIRTECAN; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; GLEMBATUMUMAB VEDOTIN; IBRITUMOMAB TIUXETAN; IMMUNOTOXIN; INOTUZUMAB OZOGAMICIN; MILATUZUMAB; MOXETUMOMAB PASUDOTOX; RANPIRNASE; RECOMBINANT CYTOKINE; RECOMBINANT GELONIN; RECOMBINANT INTERLEUKIN 2; RECOMBINANT PSEUDOMONAS EXOTOXIN; RITUXIMAB; TOSITUMOMAB I 131; TRASTUZUMAB EMTANSINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VEDOTIN; VELTUZUMAB;

ACUTE LYMPHOCYTIC LEUKEMIA; ADVANCED CANCER; ALLOGENEIC STEM CELL TRANSPLANTATION; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CAPILLARY LEAK SYNDROME; CELL SURFACE; COMPLEMENTARITY DETERMINING REGION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG CONJUGATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG TREATMENT FAILURE; EFFECTOR CELL; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; HYPERTRANSAMINASEMIA; IC 50; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOGENICITY; IMMUNOTHERAPY; IN VIVO STUDY; INTERNALIZATION; ISOTOPE LABELING; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LOSS OF VISUAL ACUITY; LYMPHOMA; MAXIMUM TOLERATED DOSE; METASTASIS; NONHUMAN; PANCREAS CANCER; PHARMACOKINETICS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLASMA CLEARANCE; PROGRESSION FREE SURVIVAL; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOIMMUNOASSAY; RADIOIMMUNOTHERAPY; REVIEW; SINGLE DRUG DOSE; SOLID TUMOR; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR LOCALIZATION; VISUAL DISORDER;

ANIMALS; ANTIBODIES; HUMANS; IMMUNOCONJUGATES; IMMUNOTHERAPY; IMMUNOTOXINS; NEOPLASMS; RADIOIMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84865326271     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.693472     Document Type: Review

References (198)

1. Holstein SA, Hohl RJ. Therapeutic additions and possible deletions in oncology in 2011. Clin Pharmacol Ther 2012;91:15-17
2. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975;256:495-7
3. Riechmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;332:323-7 (Pubitemid 18091075)
4. Shuptrine CW, Surana R, Weiner LM. Monoclonal antibodies for the treatment of cancer. Semin Cancer Biol 2012;22:3-13
5. Altshuler EP, Serebryanaya DV, Katrukha AG. Generation of recombinant antibodies and means for increasing their affinity. Biochemistry (Mosc) 2010;75:1584-605
6. Carter PJ. Introduction to current and future protein therapeutics: a protein engineering perspective. Exp Cell Res 2011;317:1261-9
7. Igawa T, Tsunoda H, Kuramochi T, et al. Engineering the variable region of therapeutic IgG antibodies. mAbs 2011;3:243-52
8. Jeong KJ, Jang SH, Velmurugan N. Recombinant antibodies: engineering and production in yeast and bacterial hosts. Biotechnol J 2011;6:16-27
9. Kaneko E, Niwa R. Optimizing therapeutic antibody function: progress with Fc domain engineering. BioDrugs 2011;25:1-11
10. Kontermann RE. Alternative antibody formats. Curr Opin Mol Ther 2010;12:176-83
11. Gebauer M, Skerra A. Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 2009;13:245-55
12. Magliani W, Conti S, Salati A, et al. Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr Med Chem 2004;11:1793-800 (Pubitemid 38821344)
13. Zhao L, Liu Z, Fan D. Overview of mimotopes and related strategies in tumor vaccine development. Expert Rev Vaccines 2008;7:1547-55
14. Feldwisch J, Tolmachev V, Lendel C, et al. Design of an optimized scaffold for affibody molecules. J Mol Biol 2010;398:232-47
15. Lofblom J, Feldwisch J, Tolmachev V, et al. Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. FEBS Lett 2010;584:2670-80
16. Keizer RJ, Huitema AD, Schellens JH, Beijnen JH. Clinical pharmacokinetics of therapeutic monoclonal antibodies. Clin Pharmacokinet 2010;49:493-507
17. Porter RR. A chemical study of rabbit antiovalbumin. Biochem J 1950;46:473-8
18. Nisonoff A, Wissler FC, Lipman LN, Woernley DL. Separation of univalent fragments from the bivalent rabbit antibody molecule by reduction of disulfide bonds. Arch Biochem Biophys 1960;89:230-44
19. Edelman GM, Poulik MD. Studies on structural units of the gamma-globulins. J Exp Med 1961;113:861-84
20. Yan L, Hsu K, Beckman RA. Antibody-based therapy for solid tumors. Cancer J 2008;14:178-83
21. Kontermann RE. Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs 2009;23:93-109
22. Olafsen T, Wu AM. Antibody vectors for imaging. Semin Nucl Med 2010;40:167-81
23. Bird RE, Hardman KD, Jacobson JW, et al. Single-chain antigen-binding proteins. Science 1988;242:423-6
24. Haber E. Engineered antibodies as pharmacological tools. Immunol Rev 1992;130:189-212 (Pubitemid 23014847)
25. Kipriyanov SM. Generation of bispecific and tandem diabodies. Methods Mol Biol 2009; 562:177-93
26. Hu S, Shively L, Raubitschek A, et al. Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res 1996;56:3055-61
27. Olafsen T, Kenanova VE, Wu AM. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat Protocol 2006;1:2048-60 (Pubitemid 46773329)
28. Nuttall SD, Irving RA, Hudson PJ. Immunoglobulin VH domains and beyond: design and selection of single-domain binding and targeting reagents. Curr Pharm Biotechnol 2000;1:253-63
29. Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotechnol 2005;23:1126-36 (Pubitemid 41486394)
30. Saerens D, Ghassabeh GH, Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr Opin Pharmacol 2008;8:600-8
31. Goldenberg DM, Sharkey RM, Paganelli G, et al. Antibody pretargeting advances cancer radioimmunodetection and radioimmunotherapy. J Clin Oncol 2006;24:823-34 (Pubitemid 46671186)
32. Sharkey RM, Goldenberg DM. Novel radioimmunopharmaceuticals for cancer imaging and therapy. Curr Opin Investig Drugs 2008;9:1302-16
33. Pressman D. The zone of localization of antibodies; the specific localization of antibodies to rat kidney. Cancer 1949;2:697-700
34. Pressman D, Korngold L. The in vivo localization of anti-Wagner- osteogenic-sarcoma antibodies. Cancer 1953;6:619-23
35. Goldenberg DM, DeLand F, Kim E, et al. Use of radiolabeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl J Med 1978;298:1384-6
36. Goldenberg DM, Gaffar SA, Bennett SJ, Beach JL. Experimental radioimmunotherapy of a xenografted human colonic tumor (GW-39) producing carcinoembryonic antigen. Cancer Res 1981; 41:4354-60 (Pubitemid 12201340)
37. Goldenberg DM, Preston DF, Primus FJ, Hansen HJ. Photoscan localization of GW-39 tumors in hamsters using radiolabeled anticarcinoembryonic antigen immunoglobulin G. Cancer Res 1974;34:1-9
38. Leichner PK, Klein JL, Garrison JB, et al. Dosimetry of 131I-labeled anti-ferritin in hepatoma: a model for radioimmunoglobulin dosimetry. Int J Radiat Oncol Biol Phys 1981;7:323-33 (Pubitemid 11112589)
39. Order SE, Klein JL, Ettinger D, et al. Use of isotopic immunoglobulin in therapy. Cancer Res 1980; 40:3001-7
40. Larson SM, Carrasquillo JA, McGuffin RW, et al. Use of I-131 labeled, murine Fab against a high molecular weight antigen of human melanoma: preliminary experience. Radiology 1985; 155:487-92 (Pubitemid 15033144)
41. Adams DA, DeNardo GL, DeNardo SJ, et al. Radioimmunotherapy of human lymphoma in athymic, nude mice as monitored by 31P nuclear magnetic resonance. Biochem Biophys Res Commun 1985;131:1020-7 (Pubitemid 16224992)
42. Badger CC, Krohn KA, Shulman H, et al. Experimental radioimmunotherapy of murine lymphoma with 131I-labeled anti-T-cell antibodies. Cancer Res 1986;46:6223-8 (Pubitemid 17221760)
43. Rosen ST, Zimmer AM, Goldman-Leikin R, et al. Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol 1987;5:562-73 (Pubitemid 17062493)
44. DeNardo SJ, DeNardo GL, O'Grady LF, et al. Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers 1987;2:49-53
45. Goldman-Leikin RE, Kaplan EH, Zimmer AM, et al. Long-term persistence of human anti-murine antibody responses following radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphoma patients using 131I-T101. Exp Hematol 1988; 16:861-4
46. Press OW, Eary JF, Badger CC, et al. Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J Clin Oncol 1989;7:1027-38 (Pubitemid 19196525)
47. DeNardo GL, DeNardo SJ, O'Grady LF, et al. Fractionated radioimmunotherapy of B-cell malignancies with 131I-Lym-1. Cancer Res 1990;50:1014s-6s (Pubitemid 20054260)
48. Parker BA, Vassos AB, Halpern SE, et al. Radioimmunotherapy of human B-cell lymphoma with 90Y-conjugated antiidiotype monoclonal antibody. Cancer Res 1990;50:1022s-8s (Pubitemid 20054262)
49. Press OW, Eary JF, Badger CC, et al. High-dose radioimmunotherapy of B cell lymphomas. Front Radiat Ther Oncol 1990;24:204-13
50. Goldenberg DM, Horowitz JA, Sharkey RM, et al. Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody. J Clin Oncol 1991;9:548-64
51. Buchsbaum DJ, Wahl RL, Glenn SD, et al. Improved delivery of radiolabeled anti-B1 monoclonal antibody to Raji lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res 1992;52:637-42
52. Buchsbaum DJ, Wahl RL, Normolle DP, Kaminski MS. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts. Cancer Res 1992;52:6476-81
53. Kaminski MS, Fig LM, Zasadny KR, et al. Imaging, dosimetry, and radioimmunotherapy with iodine 131-labeled anti-CD37 antibody in B-cell lymphoma. J Clin Oncol 1992;10:1696-711 (Pubitemid 23059946)
54. Eary JF, Press OW, Badger CC, et al. Imaging and treatment of B-cell lymphoma. J Nucl Med 1990;31:1257-68 (Pubitemid 20245918)
55. Press OW, Eary JF, Appelbaum FR, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24 (Pubitemid 23306322)
56. Kaminski MS, Zasadny KR, Francis IR, et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993;329:459-65 (Pubitemid 23222331)
57. Wahl RL. Tositumomab and 131I therapy in non-Hodgkin's lymphoma. J Nucl Med 2005;46(Suppl 1):128S-40S (Pubitemid 47619028)
58. Davis TA, Kaminski MS, Leonard JP, et al. The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res 2004;10:7792-8 (Pubitemid 39587516)
59. Knox SJ, Goris ML, Trisler K, et al. Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res 1996;2:457-70 (Pubitemid 26100047)
60. Witzig TE, White CA, Wiseman GA, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999;17:3793-803
61. Maloney DG, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997;15:3266-74 (Pubitemid 27419340)
62. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95 (Pubitemid 27392702)
63. Witzig TE, Gordon LI, Cabanillas F, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 2002;20:2453-63 (Pubitemid 34525730)
64. Morschhauser F, Kraeber-Bodere F, Wegener WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol 2010;28:3709-16
65. Wahl RL, Zasadny KR, MacFarlane D, et al. Iodine-131 anti-B1 antibody for B-cell lymphoma: an update on the Michigan Phase I experience. J Nucl Med 1998;39:21S-7S (Pubitemid 28371372)
66. Sharkey RM, Press OW, Goldenberg DM. A re-examination of radioimmunotherapy in the treatment of non-Hodgkin lymphoma: prospects for dual-targeted antibody/radioantibody therapy. Blood 2009;113:3891-5
67. Mattes MJ, Sharkey RM, Karacay H, et al. Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res 2008; 14:6154-60
68. Gulec SA, Cohen SJ, Pennington KL, et al. Treatment of advanced pancreatic carcinoma with 90Y-Clivatuzumab Tetraxetan: a phase I single-dose escalation trial. Clin Cancer Res 2011;17:4091-100
69. Ocean AJ, Guarino MJ, Pennington KL, et al. Activity of fractionated radioimmunotherapy with clivatuzumab tetraxetan combined with low-dose gemcitabine (Gem) in advanced pancreatic cancer (APC). J Clin Oncol 2011;29:abstract 240
70. Ocean AJ, Pennington KL, Guarino MJ, et al. Fractionated radioimmunotherapy (RAIT) with 90Y-clivatuzumab tetraxetan (90Y-hPAM4) and low-dose gemcitabine is active in advanced pancreatic cancer: a phase I trial. Cancer 2012;doi: 10.1002/cncr.27592
71. Sharkey RM, Pykett MJ, Siegel JA, et al. Radioimmunotherapy of the GW-39 human colonic tumor xenograft with 131I-labeled murine monoclonal antibody to carcinoembryonic antigen. Cancer Res 1987;47:5672-7 (Pubitemid 18046765)
72. Siegel JA, Pawlyk DA, Lee RE, et al. Tumor, red marrow, and organ dosimetry for 131I-labeled anti-carcinoembryonic antigen monoclonal antibody. Cancer Res 1990;50:1039s-42s (Pubitemid 20054265)
73. Liersch T, Meller J, Kulle B, et al. Phase II trial of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal metastases in the liver: five-year safety and efficacy results. J Clin Oncol 2005;23:6763-70 (Pubitemid 46190272)
74. Liersch T, Meller J, Bittrich M, et al. Update of carcinoembryonic antigen radioimmunotherapy with 131I-labetuzumab after salvage resection of colorectal liver metastases: comparison of outcome to a contemporaneous control group. Ann Surg Oncol 2007;14:2577-90 (Pubitemid 47389553)
75. Reardan DT, Meares CF, Goodwin DA, et al. Antibodies against metal chelates. Nature 1985;316:265-8 (Pubitemid 15073694)
76. Axworthy DB, Reno JM, Hylarides MD, et al. Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity. Proc Natl Acad Sci USA 2000;97:1802-7 (Pubitemid 30118523)
77. Karacay H, Brard PY, Sharkey RM, et al. Therapeutic advantage of pretargeted radioimmunotherapy using a recombinant bispecific antibody in a human colon cancer xenograft. Clin Cancer Res 2005;11:7879-85 (Pubitemid 41611634)
78. Karacay H, Sharkey RM, Gold DV, et al. Pretargeted radioimmunotherapy of pancreatic cancer xenografts: TF10-90Y-IMP-288 alone and combined with gemcitabine. J Nucl Med 2009;50:2008-16
79. Schoffelen R, Sharkey RM, Goldenberg DM, et al. Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga-and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther 2010;9:1019-27
80. Schoffelen R, van der Graaf WT, Franssen G, et al. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. J Nucl Med 2010;51:1780-7
81. Sharkey RM, Cardillo TM, Rossi EA, et al. Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med 2005;11:1250-5 (Pubitemid 43093674)
82. Sharkey RM, Goldenberg DM. Advances in radioimmunotherapy in the age of molecular engineering and pretargeting. Cancer Invest 2006;24:82-97 (Pubitemid 43250654)
83. Sharkey RM, Karacay H, Johnson CR, et al. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma. J Nucl Med 2009;50:444-53
84. Sharkey RM, Karacay H, Litwin S, et al. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody. Cancer Res 2008;68:5282-90
85. Sharkey RM, Karacay H, Vallabhajosula S, et al. Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology 2008;246:497-507
86. Chatal JF, Campion L, Kraeber-Bodere F, et al. Survival improvement in patients with medullary thyroid carcinoma who undergo pretargeted anti-carcinoembryonic-antigen radioimmunotherapy: a collaborative study with the French Endocrine Tumor Group. J Clin Oncol 2006;24:1705-11 (Pubitemid 46622142)
87. Schoffelen R, van der Graaf WT, Sharkey RM, et al. Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. EJNMMI Res 2012;2:5
88. Sharkey RM, Rossi EA, McBride WJ, et al. Recombinant bispecific monoclonal antibodies prepared by the dock-and-lock strategy for pretargeted radioimmunotherapy. Semin Nucl Med 2010;40:190-203
89. Kyriakos RJ, Shih LB, Ong GL, et al. The fate of antibodies bound to the surface of tumor cells in vitro. Cancer Res 1992;52:835-42
90. Hanna R, Ong GL, Mattes MJ. Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Cancer Res 1996;56:3062-8 (Pubitemid 26199752)
91. Jain RK. Taming vessels to treat cancer. Sci Am 2008;298:56-63 (Pubitemid 351182556)
92. Stylianopoulos T, Poh MZ, Insin N, et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J 2010;99:1342-9
93. Baish JW, Stylianopoulos T, Lanning RM, et al. Scaling rules for diffusive drug delivery in tumor and normal tissues. Proc Natl Acad Sci USA 2011;108:1799-803
94. Fujimori K, Covell DG, Fletcher JE, Weinstein JN. A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990;31:1191-8 (Pubitemid 20213280)
95. Saga T, Neumann RD, Heya T, et al. Targeting cancer micrometastases with monoclonal antibodies: a binding-site barrier. Proc Natl Acad Sci USA 1995;92:8999-9003
96. Gerber HP, Senter PD, Grewal IS. Antibody drug-conjugates targeting the tumor vasculature: current and future developments. mAbs 2009;1:247-53
97. Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates. mAbs 2012;4:349-61
98. Carter PJ, Senter PD. Antibody-drug conjugates for cancer therapy. Cancer J 2008;14:154-69
99. Kellogg BA, Garrett L, Kovtun Y, et al. Disulfide-linked antibody-maytansinoid conjugates: optimization of in vivo activity by varying the steric hindrance at carbon atoms adjacent to the disulfide linkage. Bioconjug Chem 2011;22:717-27
100. Shen BQ, Xu K, Liu L, et al. Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates. Nat Biotechnol 2012;30:184-9
101. Sun X, Widdison W, Mayo M, et al. Design of antibody-maytansinoid conjugates allows for efficient detoxification via liver metabolism. Bioconjug Chem 2011;22:728-35
102. Zhao RY, Wilhelm SD, Audette C, et al. Synthesis and evaluation of hydrophilic linkers for antibody-maytansinoid conjugates. J Med Chem 2011;54:3606-23
103. Govindan SV, Goldenberg DM. Designing immunoconjugates for cancer therapy. Expert Opin Biol Ther 2012; In press
104. Moon SJ, Govindan SV, Cardillo TM, et al. Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy. J Med Chem 2008;51:6916-26
105. Moon SJ, Tat F, Sheerin A, et al. Cross-linker evaluation in the design of antibody-SN-38 conjugates for cancer therapy [abstract 2439]. Proc Am Assoc Cancer Res 2010;51:591
106. Govindan SV, Cardillo TM, Moon SJ, et al. CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clin Cancer Res 2009;15:6052-61
107. Stein R, Govindan SV, Hayes M, et al. Advantage of a residualizing iodine radiolabel in the therapy of a colon cancer xenograft targeted with an anticarcinoembryonic antigen monoclonal antibody. Clin Cancer Res 2005;11:2727-34 (Pubitemid 40569475)
108. Sharkey RM, Karacay H, Govindan SV, Goldenberg DM. Combination radioimmunotherapy and chemoimmunotherapy involving different or the same targets improves therapy of human pancreatic carcinoma xenograft models. Mol Cancer Ther 2011;10:1072-81
109. Mathijssen RH, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94 (Pubitemid 32751614)
110. Garcia-Carbonero R, Supko JG. Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins. Clin Cancer Res 2002;8:641-61 (Pubitemid 34742090)
111. Shih LB, Lu HH, Xuan H, Goldenberg DM. Internalization and intracellular processing of an anti-B-cell lymphoma monoclonal antibody, LL2. Int J Cancer 1994;56:538-45 (Pubitemid 24094405)
112. Afshar S, Olafsen T, Wu AM, Morrison SL. Characterization of an engineered human purine nucleoside phosphorylase fused to an anti-her2/neu single chain Fv for use in ADEPT. J Exp Clin Cancer Res 2009;28:147
113. Bagshawe KD. Targeting: the ADEPT story so far. Curr Drug Targets 2009;10:152-7
114. Schellmann N, Deckert PM, Bachran D, et al. Targeted enzyme prodrug therapies. Mini Rev Med Chem 2010;10:887-904
115. Trowbridge IS, Domingo DL. Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumour cells. Nature 1981;294:171-3 (Pubitemid 12217978)
116. Domingo DL, Trowbridge IS. Transferrin receptor as a target for antibody-drug conjugates. Methods Enzymol 1985;112:238-47 (Pubitemid 15036585)
117. Friden PM, Walus LR, Musso GF, et al. Anti-transferrin receptor antibody and antibody-drug conjugates cross the blood-brain barrier. Proc Natl Acad Sci USA 1991;88:4771-5 (Pubitemid 21914624)
118. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002;54:561-87 (Pubitemid 35351196)
119. Daniels TR, Bernabeu E, Rodriguez JA, et al. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012;1820:291-317
120. Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol 2012;503:269-92
121. Burton JD, Ely S, Reddy PK, et al. CD74 is expressed by multiple myeloma and is a promising target for therapy. Clin Cancer Res 2004;10:6606-11 (Pubitemid 39346557)
122. Beswick EJ, Reyes VE. CD74 in antigen presentation, inflammation, and cancers of the gastrointestinal tract. World J Gastroenterol 2009;15:2855-61
123. Gold DV, Stein R, Burton J, Goldenberg DM. Enhanced expression of CD74 in gastrointestinal cancers and benign tissues. Int J Clin Exp Pathol 2010;4:1-12
124. Hansen HJ, Ong GL, Diril H, et al. Internalization and catabolism of radiolabelled antibodies to the MHC class-II invariant chain by B-cell lymphomas. Biochem J 1996;320:293-300
125. Griffiths GL, Mattes MJ, Stein R, et al. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate. Clin Cancer Res 2003;9:6567-71 (Pubitemid 38031846)
126. Chang CH, Sapra P, Vanama SS, et al. Effective therapy of human lymphoma xenografts with a novel recombinant ribonuclease/anti-CD74 humanized IgG4 antibody immunotoxin. Blood 2005;106:4308-14 (Pubitemid 41775941)
127. Sapra P, Stein R, Pickett J, et al. Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res 2005;11:5257-64 (Pubitemid 41003714)
128. Stein R, Mattes MJ, Cardillo TM, et al. CD74: a new candidate target for the immunotherapy of B-cell neoplasms. Clin Cancer Res 2007;13:5556s-63s (Pubitemid 47510387)
129. Giles FJ, Kantarjian HM, Kornblau SM, et al. Mylotarg™ (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer 2001;92:406-13 (Pubitemid 32664448)
130. Wadleigh M, Richardson PG, Zahrieh D, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102:1578-82 (Pubitemid 37022544)
131. Rajvanshi P, Shulman HM, Sievers EL, McDonald GB. Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood 2002;99:2310-14 (Pubitemid 34525414)
132. Thomas X. Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia. Expert Opin Investig Drugs 2012;21:871-8
133. Advani A, Coiffier B, Czuczman MS, et al. Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol 2010;28:2085-93
134. Kantarjian H, Thomas D, Jorgensen J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 2012;13:403-11
135. Lo Coco F, Ammatuna E, Noguera N. Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin. Clin Adv Hematol Oncol 2006;4:57-62, 76-7
136. de Vries JF, Zwaan CM, De Bie M, et al. The novel calicheamicin- conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells. Leukemia 2012;26:255-64
137. Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010;363:1812-21
138. Furtado M, Rule S. Emerging pharmacotherapy for relapsed or refractory Hodgkin's lymphoma: focus on brentuximab vedotin. Clin Med Insights Oncol 2012;6:31-9
139. Gualberto A. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies. Expert Opin Investig Drugs 2012;21:205-16
140. Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012;doi: 10.1200/JCO.2011.38.0410
141. Burris HA III, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405
142. LoRusso PM, Weiss D, Guardino E, et al. Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer. Clin Cancer Res 2011;17:6437-47
143. Tse KF, Jeffers M, Pollack VA, et al. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma. Clin Cancer Res 2006;12:1373-82 (Pubitemid 43342531)
144. Naumovski L, Junutula Jr. Glembatumumab vedotin, a conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer. Curr Opin Mol Ther 2010;12:248-57
145. Rose AA, Grosset AA, Dong Z, et al. Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer. Clin Cancer Res 2010;16:2147-56
146. Keir CH, Vahdat LT. The use of an antibody drug conjugate, glembatumumab vedotin (CDX-011), for the treatment of breast cancer. Expert Opin Biol Ther 2012;12:259-63
147. Sapra P, Hooper AT, O'Donnell CJ, Gerber HP. Investigational antibody drug conjugates for solid tumors. Expert Opin Investig Drugs 2011;20:1131-49
148. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol 2010;14:529-37
149. Alley SC, Zhang X, Okeley NM, et al. The pharmacologic basis for antibody-auristatin conjugate activity. J Pharmacol Exp Ther 2009;330:932-8
150. Beltran PJ, Mitchell P, Cajulis E, et al. Efficacy of AMG 479, alone and in combination with cisplatin, in ovarian carcinoma xenograft models. Mol Cancer Ther 2009;8:abstract C172
151. Derycke MS, Pambuccian SE, Gilks CB, et al. Nectin 4 overexpression in ovarian cancer tissues and serum: potential role as a serum biomarker. Am J Clin Pathol 2010;134:835-45
152. Fabre-Lafay S, Monville F, Garrido-Urbani S, et al. Nectin-4 is a new histological and serological tumor associated marker for breast cancer. BMC Cancer 2007;7:73 (Pubitemid 46785011)
153. Golfier S, Kahnert A, Heisler I, et al. Identification of BAY 94-9343, a mesothelin antibody-drug conjugate (ADC): characterization and anti-tumor activity in mesothelin-positive preclinical tumor models [abstract 1754]. Proc Am Assoc Cancer Res 2011;52:419
154. Gudas JM, An Z, Morrison RK, et al. ASG-5ME: A novel antibody-drug conjugate (ADC) therapy for prostate, pancreatic, and gastric cancers [abstract 230]. Genitourinary Cancers Symposium 2010
155. Hamblett KJ, Kozlosky CJ, Liu H, et al. AMG595, a novel antibody drug conjugate approach for targeting EGFRVIII-espressing glioblastoma. Neurol Oncol 2011;13:abstract ET-36
156. Oflazoglu E, Stone IJ, Gordon K, et al. Potent anticarcinoma activity of the humanized anti-CD70 antibody h1F6 conjugated to the tubulin inhibitor auristatin via an uncleavable linker. Clin Cancer Res 2008;14:6171-80
157. Takano A, Ishikawa N, Nishino R, et al. Identification of nectin-4 oncoprotein as a diagnostic and therapeutic target for lung cancer. Cancer Res 2009;69:6694-703
158. Thompson JA, Forero-Torres A, Heath EI, et al. The effect of SGN-75, a novel antibody-drug conjugate (ADC), in treatment of patients with renal cell carcinoma (RCC) or non-Hodgkin lymphoma (NHL): a phase I study. J Clin Oncol 2011;29:abstract 3071
159. Li YM, Hall WA. Targeted toxins in brain tumor therapy. Toxins 2010;2:2645-62
160. Choudhary S, Mathew M, Verma RS. Therapeutic potential of anticancer immunotoxins. Drug Discov Today 2011;16:495-503
161. Dosio F, Brusa P, Cattel L. Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components. Toxins 2011;3:848-83
162. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I. Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 2011;71:6300-9
163. Kreitman RJ, Pastan I. Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 2011;17:6398-405
164. Mathew J, Perez EA. Trastuzumab emtansine in human epidermal growth factor receptor 2-positive breast cancer: a review. Curr Opin Oncol 2011;23:594-600
165. Pasquetto MV, Vecchia L, Covini D, et al. Targeted drug delivery using immunoconjugates: principles and applications. J Immunother 2011;34:611-28
166. Schindler J, Gajavelli S, Ravandi F, et al. A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol 2011;154:471-6
167. Weldon JE, Pastan I. A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 2011;278:4683-700
168. Zielinski R, Lyakhov I, Hassan M, et al. HER2-affitoxin: a potent therapeutic agent for the treatment of HER2-overexpressing tumors. Clin Cancer Res 2011;17:5071-81
169. Adkins I, Holubova J, Kosova M, Sadilkova L. Bacteria and their toxins tamed for immunotherapy. Curr Pharm Biotechnol 2012
170. Lyu MA, Cao YJ, Mohamedali KA, Rosenblum MG. Cell-targeting fusion constructs containing recombinant gelonin. Methods Enzymol 2012;502:167-214
171. Onda M, Beers R, Xiang L, et al. Recombinant immunotoxin against B-cell
172. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88 (Pubitemid 32112849)
173. Hassan R, Bullock S, Premkumar A, et al. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 2007;13:5144-9 (Pubitemid 47502082)
174. Kreitman RJ, Tallman MS, Robak T, et al. Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia. J Clin Oncol 2012;30:1822-28
175. Mussai F, Campana D, Bhojwani D, et al. Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia. Br J Haematol 2010;150:352-8
176. Wayne AS, Bhojwani D, Silverman LB, et al. A Novel Anti-CD22 Immunotoxin, moxetumomab pasudotox: phase I study in pediatric Acute Lymphoblastic Leukemia (ALL). ASH Annual Meeting Abstracts 2011;118:248
177. Herrera L, Bostrom B, Gore L, et al. A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2009;31:936-41
178. Herrera L, Farah RA, Pellegrini VA, et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia 2000;14:853-8 (Pubitemid 30235063)
179. Mohamedali KA, Ran S, Gomez-Manzano C, et al. Cytotoxicity of VEGF(121)/rGel on vascular endothelial cells resulting in inhibition of angiogenesis is mediated via VEGFR-2. BMC Cancer 2011;11:358
180. Lyu MA, Rai D, Ahn KS, et al. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia 2010;12:366-75
181. Cao Y, Marks JD, Huang Q, et al. Single-chain antibody-based immunotoxins targeting Her2/neu: design optimization and impact of affinity on antitumor efficacy and off-target toxicity. Mol Cancer Ther 2012;11:143-53
182. Porta C, Paglino C, Mutti L. Ranpirnase and its potential for the treatment of unresectable malignant mesothelioma. Biol Targets Ther 2008;2:601-9
183. Chang CH, Gupta P, Michel R, et al. Ranpirnase (frog RNase) targeted with a humanized, internalizing, anti-Trop-2 antibody has potent cytotoxicity against diverse epithelial cancer cells. Mol Cancer Ther 2010;9:2276-86
184. Rossi EA, Goldenberg DM, Chang CH. The Dock-and-Lock method combines recombinant engineering with site-specific covalent conjugation to generate multifunctional structures. Bioconjug Chem 2012;23:309-23
185. Rossi EA, Chan E, Cardillo TM, et al. Potent ribonuclease-based immunotoxins comprising quadruple ranpirnase (Rap) site-specifically conjugated to B-cell lymphoma-targeting antibodies [abstract 5345]. Proc Am Assoc Cancer Res 2010;51:1295
186. Cardillo TM, Rossi EA, Arrojo R, et al. A novel immunotoxin comprising quadruple RNase tethered to an internalizing anti-TROP-2 humanized MAb shows potent cytotoxicity against diverse solid tumors in vitro [abstract 5346]. Proc Am Assoc Cancer Res 2010;51:1296
187. Lode HN, Xiang R, Becker JC, et al. Immunocytokines: a promising approach to cancer immunotherapy. Pharmacol Ther 1998;80:277-92 (Pubitemid 28537824)
188. Frey K, Zivanovic A, Schwager K, Neri D. Antibody-based targeting of interferon-alpha to the tumor neovasculature: a critical evaluation. Integr Biol (Camb) 2011;3:468-78
189. Pasche N, Neri D. Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today 2012;http://dx.doi.org/10.1016/j. drudis.2012.01.007
190. Yamane BH, Hank JA, Albertini MR, Sondel PM. The development of antibody-IL-2 based immunotherapy with hu14.18-IL2 (EMD-273063) in melanoma and neuroblastoma. Expert Opin Investig Drugs 2009;18:991-1000
191. Gillies SD, Lan Y, Hettmann T, et al. A low-toxicity IL-2-based immunocytokine retains antitumor activity despite its high degree of IL-2 receptor selectivity. Clin Cancer Res 2011;17:3673-85
192. Johannsen M, Spitaleri G, Curigliano G, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010;46:2926-35
193. Eigentler TK, Weide B, de Braud F, et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 2011;17:7732-42
194. Kontermann RE. Antibody-cytokine fusion proteins. Arch Biochem Biophys 2012http://dx.doi.org/10.1016/j. abb.2012.03.001
195. Chang CH, Rossi EA, Goldenberg DM. The dock and lock method: a novel platform technology or building multivalent, multifunctional structures of defined composition with retained bioactivity. Clin Cancer Res 2007;13:5586s-91s (Pubitemid 47510391)
196. Rossi EA, Goldenberg DM, Cardillo TM, et al. CD20-targeted tetrameric interferon-alpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood 2009;114:3864-71
197. Rossi EA, Rossi DL, Cardillo TM, et al. Preclinical studies on targeted delivery of multiple IFNalpha2b to HLA-DR in diverse hematologic cancers. Blood 2011;118:1877-84
198. Rossi EA, Rossi DL, Stein R, et al. A bispecific antibody-IFNalpha2b immunocytokine targeting CD20 and HLA-DR is highly toxic to human lymphoma and multiple myeloma cells. Cancer Res 2010;70:7600-9